The Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Pradaxa as the first oral blood thinning medication to treat children aged three months to less than 12 years old in the US. The FDA has cleared Pradaxa (dabigatran etexilate) for use in children with venous thromboembolism, immediately after treatment with a blood thinner given by injection for at least five days. Pradaxa oral pellets have also been approved to prevent recurrent clots among children aged three months to less than 12 years old, who have complete treatment for their first venous thromboembolism. Lastly, the drug has been approved in capsule form to treat blood clots in patients eight years and older with venous thromboembolism, directly after they have been treated with a blood thinner given for at least five days, and to prevent clots in patients aged eight years and older who have completed treatment for their first venous ...
AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.
Link:https://www.mobihealthnews.com/content/how-central-east-africas-tech-renaissance-shaping-its-healthcare-future
Klara, a New York-based healthcare messaging system, just landed another $11.5 million in Series A funding round led by FirstMark Capital in addition to participants like Project A Ventures, Lerer Hippeau, Atlantic Labs, and other investors.
HitGen and Merck have updated their licensing agreement to a full-fledged drug discovery collaboration in order to screen DNA-encoded libraries for new small-molecule assets.
Janssen Korea becomes yet another drugmaker to shut its Hyangnam plant in Hwaseong, South Korea, by 2021, stranding an uncounted number of employees.
96-week data on doravirine, Merck’s HIV drug, was posted by the drugmaker recently. Merck expects it to outrun drugs like Bristol-Myers Squibb’s Sustiva in combination regimens and antiretroviral drugs from AbbVie and Johnson & Johnson in viral suppression.
The opening of a new Biomedical Blockchain Research Center was announced by the Icahn School of Medicine at Mount Sinai and the Institute for Next Generation Healthcare which aims to solve healthcare and medical science issues with new technologies and data.
Pharmaceutical giant AstraZeneca and integrated health services provider Geisinger are partnering to create an app suite, which by connecting to electronic health records (EHR) aims to upgrade asthma care.
In the United States alone, there are an estimated 20,000 people living with amyotrophic lateral sclerosis (ALS), also called as Lou Gehrig's disease. The fatal disease destroys the nerve cells which control breathing, walking, and eating. Very few people survive more than three years after being diagnosed.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.